Ignite Creation Date:
2025-12-25 @ 2:08 AM
Ignite Modification Date:
2025-12-26 @ 3:28 AM
Study NCT ID:
NCT05171660
Status:
RECRUITING
Last Update Posted:
2025-06-15
First Post:
2021-11-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-02-08
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-12-30
Completion Date Type:
ESTIMATED
First Submit Date:
2021-11-08
First Submit QC Date:
None
Study First Post Date:
2021-12-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-06-11
Last Update Post Date:
2025-06-15
Last Update Post Date Type:
ACTUAL